CL2014000365A1 - Compound 4- (8-methoxy-1 - ((r) -1-methoxypropan-2-yl) -2- (tetrahydro-2h-pyran-4-yl) -1h-imidazo [4,5-c] quinolin- 7-yl) -3,5-dimethylisoxazole, brodominium inhibitor; pharmaceutical composition; pharmaceutical product; treatment procedure; and its use to treat an autoimmune and / or chronic inflammatory condition and cancer, among others. - Google Patents

Compound 4- (8-methoxy-1 - ((r) -1-methoxypropan-2-yl) -2- (tetrahydro-2h-pyran-4-yl) -1h-imidazo [4,5-c] quinolin- 7-yl) -3,5-dimethylisoxazole, brodominium inhibitor; pharmaceutical composition; pharmaceutical product; treatment procedure; and its use to treat an autoimmune and / or chronic inflammatory condition and cancer, among others.

Info

Publication number: CL2014000365A1
Authority: CL; Chile
Prior art keywords: brodominium; dimethylisoxazole; methoxypropan; quinolin; imidazo
Prior art date: 2011-08-17

Application number

CL2014000365A

Other languages

Spanish (es)

Inventor

Emmanuel Hubert Demont

Katherine Louise Jones

Robert J Watson

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-17

Filing date

2014-02-13

Publication date

2014-07-11

2014-02-13 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2014-07-11 Publication of CL2014000365A1 publication Critical patent/CL2014000365A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL2014000365A 2011-08-17 2014-02-13 Compound 4- (8-methoxy-1 - ((r) -1-methoxypropan-2-yl) -2- (tetrahydro-2h-pyran-4-yl) -1h-imidazo [4,5-c] quinolin- 7-yl) -3,5-dimethylisoxazole, brodominium inhibitor; pharmaceutical composition; pharmaceutical product; treatment procedure; and its use to treat an autoimmune and / or chronic inflammatory condition and cancer, among others. CL2014000365A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1114103.3A GB201114103D0 (en)	2011-08-17	2011-08-17	Novel compounds

Publications (1)

Publication Number	Publication Date
CL2014000365A1 true CL2014000365A1 (en)	2014-07-11

Family

ID=44764570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000365A CL2014000365A1 (en)	2011-08-17	2014-02-13	Compound 4- (8-methoxy-1 - ((r) -1-methoxypropan-2-yl) -2- (tetrahydro-2h-pyran-4-yl) -1h-imidazo [4,5-c] quinolin- 7-yl) -3,5-dimethylisoxazole, brodominium inhibitor; pharmaceutical composition; pharmaceutical product; treatment procedure; and its use to treat an autoimmune and / or chronic inflammatory condition and cancer, among others.

Country Status (38)

Country	Link
US (4)	US9067936B2 (en)
EP (2)	EP3150601A1 (en)
JP (1)	JP6059723B2 (en)
KR (1)	KR20140064878A (en)
CN (1)	CN103889984B (en)
AR (1)	AR087545A1 (en)
AU (1)	AU2012296914B2 (en)
BR (1)	BR112014003681A8 (en)
CA (1)	CA2843537A1 (en)
CL (1)	CL2014000365A1 (en)
CO (1)	CO6862151A2 (en)
CR (1)	CR20140076A (en)
CY (1)	CY1118370T1 (en)
DK (1)	DK2744809T3 (en)
DO (1)	DOP2014000031A (en)
EA (1)	EA023374B1 (en)
ES (1)	ES2609857T3 (en)
GB (1)	GB201114103D0 (en)
HR (1)	HRP20161674T1 (en)
HU (1)	HUE030106T2 (en)
IL (1)	IL230489A (en)
IN (1)	IN2014CN00568A (en)
JO (1)	JO3187B1 (en)
LT (1)	LT2744809T (en)
ME (1)	ME02589B (en)
MX (1)	MX350597B (en)
MY (1)	MY170729A (en)
PE (1)	PE20141406A1 (en)
PH (1)	PH12014500379A1 (en)
PL (1)	PL2744809T3 (en)
PT (1)	PT2744809T (en)
RS (1)	RS55560B1 (en)
SI (1)	SI2744809T1 (en)
SM (2)	SMT201700005T1 (en)
TW (1)	TWI558704B (en)
UA (1)	UA110838C2 (en)
UY (1)	UY34264A (en)
WO (1)	WO2013024104A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9249161B2 (en)	2010-12-02	2016-02-02	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
AR084070A1 (en)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012151512A2 (en)	2011-05-04	2012-11-08	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2012174487A2 (en)	2011-06-17	2012-12-20	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
GB201114103D0 (en) *	2011-08-17	2011-09-28	Glaxosmithkline Llc	Novel compounds
WO2013184878A1 (en)	2012-06-06	2013-12-12	Constellation Pharmaceuticals, Inc.	Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (en)	2012-06-06	2017-10-21	星宿藥物公司	Bromodomain inhibitors and uses thereof
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
MX2015007921A (en)	2012-12-21	2016-03-03	Zenith Epigenetics Corp	Novel heterocyclic compounds as bromodomain inhibitors.
EP2970285B1 (en)	2013-03-11	2019-04-17	AbbVie Inc.	Fused tetracyclic bromodomain inhibitors
CN105377851B (en)	2013-03-11	2018-07-20	密执安州立大学董事会	BET bromodomain inhibitors and methods of treatment using these inhibitors
JP2016512524A (en) *	2013-03-11	2016-04-28	アッヴィ・インコーポレイテッド	Bromodomain inhibitor
MX366703B (en) *	2013-03-15	2019-07-22	Incyte Holdings Corp	Tricyclic heterocycles as bet protein inhibitors.
TWI530499B (en) *	2013-03-28	2016-04-21	吉李德科學股份有限公司	Benzimidazolone derivatives as bromodomain inhibitors
WO2015004534A2 (en)	2013-06-21	2015-01-15	Zenith Epigenetics Corp.	Novel substituted bicyclic compounds as bromodomain inhibitors
CN105407888B (en)	2013-06-21	2019-05-21	齐尼思表观遗传学有限公司	Novel bicyclic bromodomain inhibitors
WO2015006193A1 (en)	2013-07-08	2015-01-15	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (en)	2013-07-31	2019-07-10	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	Novel quinazolinones as bromodomain inhibitors
WO2015049629A1 (en) *	2013-10-01	2015-04-09	Piramal Enterprises Limited	Imidazoquinoline compounds as bromodomain inhibitors
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en)	2013-12-19	2016-04-12	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
WO2015131005A1 (en)	2014-02-28	2015-09-03	The Regents Of The University Of Michigan	9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
SI3674302T1 (en)	2014-04-23	2023-07-31	Incyte Holdings Corporation	1h-pyrrolo(2,3-c)pyridin-7(6h)-ones and pyrazolo(3,4-c)pyridin-7(6h)-ones as inhibitors of bet proteins
PT3157928T (en)	2014-06-20	2019-05-30	Constellation Pharmaceuticals Inc	Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
ES2855225T3 (en)	2014-09-15	2021-09-23	Incyte Corp	Tricyclic heterocycles for use as BET protein inhibitors
CA2966298A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CN107406438B (en)	2014-12-17	2021-05-14	恒翼生物医药科技(上海)有限公司	Inhibitors of bromodomains
EP3253756B1 (en)	2015-02-03	2021-09-22	Trillium Therapeutics Inc.	Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
EP3262045A1 (en)	2015-02-27	2018-01-03	The Regents of The University of Michigan	9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201504689D0 (en) *	2015-03-19	2015-05-06	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201504694D0 (en)	2015-03-19	2015-05-06	Glaxosmithkline Ip Dev Ltd	Covalent conjugates
WO2016186453A1 (en) *	2015-05-20	2016-11-24	Kainos Medicine, Inc.	Quinoline derivatives as bromodomain inhibitors
WO2016196065A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016199943A1 (en) *	2015-06-11	2016-12-15	Takeda Pharmaceutical Company Limited	Heterocyclic compounds
US10836742B2 (en)	2015-08-11	2020-11-17	Neomed Institute	N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en)	2015-08-11	2019-12-10	Neomed Institute	Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
CN114605387A (en)	2015-08-12	2022-06-10	埃皮吉纳提克斯股份有限公司	Substituted benzimidazoles, their preparation and their use as medicaments
US10501459B2 (en)	2015-10-21	2019-12-10	Neomed Institute	Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US20170121347A1 (en)	2015-10-29	2017-05-04	Incyte Corporation	Amorphous solid form of a bet protein inhibitor
US10519151B2 (en)	2016-01-28	2019-12-31	Neomed Institute	Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
ES2882066T3 (en)	2016-02-15	2021-12-01	Univ Michigan Regents	Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
JP7037500B2 (en)	2016-04-06	2022-03-16	ザリージェンツオブザユニヴァシティオブミシガン	MDM2 proteolytic agent
JP7001614B2 (en)	2016-04-06	2022-02-03	ザリージェンツオブザユニヴァシティオブミシガン	Monofunctional intermediate for ligand-gated target proteolysis
AU2017250076B2 (en)	2016-04-12	2021-07-22	The Regents Of The University Of Michigan	Bet protein degraders
CR20190027A (en)	2016-06-20	2019-05-16	Incyte Corp	SOLID CRYSTAL FORMS OF A BET INHIBITOR
JP7035027B2 (en)	2016-09-13	2022-03-14	ザリージェンツオブザユニヴァシティオブミシガン	Condensation 1,4-diazepine as a BET proteolytic agent
AU2017326171B2 (en)	2016-09-13	2021-12-09	The Regents Of The University Of Michigan	Fused 1,4-oxazepines as BET protein degraders
WO2018144789A1 (en)	2017-02-03	2018-08-09	The Regents Of The University Of Michigan	Fused 1,4-diazepines as bet bromodomain inhibitors
US11267822B2 (en)	2017-09-13	2022-03-08	The Regents Of The University Of Michigan	BET bromodomain protein degraders with cleavable linkers
CN108033957A (en) *	2018-01-09	2018-05-15	中国药科大学	A kind of quinolines BET bromodomain inhibitor and its preparation method and application
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022132049A1 (en) *	2020-12-17	2022-06-23	National University Of Singapore	Treating cancers using bet inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
US7091214B2 (en)	2002-12-20	2006-08-15	3M Innovative Properties Co.	Aryl substituted Imidazoquinolines
BRPI0416128B8 (en)	2003-11-03	2021-06-22	Glaxo Group Ltd	fluid dispensing device
KR20060117329A (en)	2003-11-21	2006-11-16	노파르티스 아게	1H-imidazoquinoline derivatives as protein kinase inhibitors
EP1845988A2 (en)	2005-02-11	2007-10-24	3M Innovative Properties Company	Substituted imidazoquinolines and imidazonaphthyridines
WO2007035935A1 (en)	2005-09-23	2007-03-29	Coley Pharmaceutical Group, Inc.	METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
MX2008007864A (en)	2005-12-16	2009-03-04	Coley Pharm Group Inc	Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods.
JP2008156311A (en)	2006-12-26	2008-07-10	Institute Of Physical & Chemical Research	BRD2 bromodomain binding agent
KR101600634B1 (en) *	2007-12-28	2016-03-07	미쓰비시 타나베 파마 코퍼레이션	Antitumor agent
GB0919423D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
US9102677B2 (en) *	2009-11-05	2015-08-11	Glaxosmithkline Llc	Benzodiazepine bromodomain inhibitor
GB0919432D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
GB0919434D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
GB201106799D0 (en)	2011-04-21	2011-06-01	Glaxosmithkline Llc	Novel compounds
GB201114103D0 (en)	2011-08-17	2011-09-28	Glaxosmithkline Llc	Novel compounds

2011
- 2011-08-17 GB GBGB1114103.3A patent/GB201114103D0/en not_active Ceased
2012
- 2012-08-15 IN IN568CHN2014 patent/IN2014CN00568A/en unknown
- 2012-08-15 PL PL12748028T patent/PL2744809T3/en unknown
- 2012-08-15 ME MEP-2016-288A patent/ME02589B/en unknown
- 2012-08-15 EA EA201490200A patent/EA023374B1/en not_active IP Right Cessation
- 2012-08-15 LT LTEP12748028.3T patent/LT2744809T/en unknown
- 2012-08-15 PH PH1/2014/500379A patent/PH12014500379A1/en unknown
- 2012-08-15 WO PCT/EP2012/065918 patent/WO2013024104A1/en not_active Ceased
- 2012-08-15 CA CA2843537A patent/CA2843537A1/en not_active Abandoned
- 2012-08-15 ES ES12748028.3T patent/ES2609857T3/en active Active
- 2012-08-15 TW TW101129613A patent/TWI558704B/en not_active IP Right Cessation
- 2012-08-15 PT PT127480283T patent/PT2744809T/en unknown
- 2012-08-15 JP JP2014525437A patent/JP6059723B2/en not_active Expired - Fee Related
- 2012-08-15 PE PE2014000167A patent/PE20141406A1/en not_active Application Discontinuation
- 2012-08-15 AR ARP120102987A patent/AR087545A1/en unknown
- 2012-08-15 MX MX2014001834A patent/MX350597B/en active IP Right Grant
- 2012-08-15 BR BR112014003681A patent/BR112014003681A8/en not_active Application Discontinuation
- 2012-08-15 EP EP16192662.1A patent/EP3150601A1/en not_active Withdrawn
- 2012-08-15 HU HUE12748028A patent/HUE030106T2/en unknown
- 2012-08-15 US US14/237,905 patent/US9067936B2/en not_active Expired - Fee Related
- 2012-08-15 HR HRP20161674TT patent/HRP20161674T1/en unknown
- 2012-08-15 UA UAA201400590A patent/UA110838C2/en unknown
- 2012-08-15 RS RS20170014A patent/RS55560B1/en unknown
- 2012-08-15 MY MYPI2014700328A patent/MY170729A/en unknown
- 2012-08-15 DK DK12748028.3T patent/DK2744809T3/en active
- 2012-08-15 KR KR1020147007082A patent/KR20140064878A/en not_active Ceased
- 2012-08-15 CN CN201280040092.5A patent/CN103889984B/en not_active Expired - Fee Related
- 2012-08-15 AU AU2012296914A patent/AU2012296914B2/en not_active Ceased
- 2012-08-15 SI SI201230818A patent/SI2744809T1/en unknown
- 2012-08-15 EP EP12748028.3A patent/EP2744809B1/en active Active
- 2012-08-15 JO JOP/2012/0229A patent/JO3187B1/en active
- 2012-08-15 SM SM20170005T patent/SMT201700005T1/en unknown
- 2012-08-15 UY UY0001034264A patent/UY34264A/en not_active Application Discontinuation
2014
- 2014-01-16 IL IL230489A patent/IL230489A/en active IP Right Grant
- 2014-01-21 CO CO14011125A patent/CO6862151A2/en not_active Application Discontinuation
- 2014-02-13 CL CL2014000365A patent/CL2014000365A1/en unknown
- 2014-02-17 CR CR20140076A patent/CR20140076A/en unknown
- 2014-02-17 DO DO2014000031A patent/DOP2014000031A/en unknown
2015
- 2015-05-28 US US14/723,556 patent/US9416130B2/en not_active Expired - Fee Related
2016
- 2016-07-08 US US15/205,372 patent/US9610284B2/en not_active Expired - Fee Related
- 2016-12-16 CY CY20161101310T patent/CY1118370T1/en unknown
2017
- 2017-01-04 SM SM201700005T patent/SMT201700005B/en unknown
- 2017-02-17 US US15/435,697 patent/US9861627B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SMT201700005T1 (en)	2017-03-08
CR20140076A (en)	2014-03-19
US9861627B2 (en)	2018-01-09
PT2744809T (en)	2017-01-06
EP2744809A1 (en)	2014-06-25
US20170157113A1 (en)	2017-06-08
AU2012296914B2 (en)	2016-03-03
DOP2014000031A (en)	2014-06-01
AU2012296914A1 (en)	2014-02-13
CO6862151A2 (en)	2014-02-10
SMT201700005B (en)	2017-03-08
MX2014001834A (en)	2014-02-27
ES2609857T3 (en)	2017-04-24
PH12014500379A1 (en)	2021-07-12
CN103889984A (en)	2014-06-25
CY1118370T1 (en)	2017-06-28
MX350597B (en)	2017-09-11
TWI558704B (en)	2016-11-21
IL230489A0 (en)	2014-03-31
NZ620263A (en)	2016-04-29
BR112014003681A2 (en)	2017-03-01
CA2843537A1 (en)	2013-02-21
US20150315184A1 (en)	2015-11-05
US9067936B2 (en)	2015-06-30
CN103889984B (en)	2016-01-13
IN2014CN00568A (en)	2015-04-03
UA110838C2 (en)	2016-02-25
DK2744809T3 (en)	2017-01-23
JP2014521735A (en)	2014-08-28
LT2744809T (en)	2016-12-27
EA023374B1 (en)	2016-05-31
ME02589B (en)	2017-06-20
US9610284B2 (en)	2017-04-04
AR087545A1 (en)	2014-04-03
US9416130B2 (en)	2016-08-16
US20160317529A1 (en)	2016-11-03
EP2744809B1 (en)	2016-10-12
WO2013024104A1 (en)	2013-02-21
EA201490200A1 (en)	2014-07-30
TW201323424A (en)	2013-06-16
PL2744809T3 (en)	2017-08-31
BR112014003681A8 (en)	2018-01-23
IL230489A (en)	2016-07-31
KR20140064878A (en)	2014-05-28
MY170729A (en)	2019-08-27
RS55560B1 (en)	2017-05-31
HRP20161674T1 (en)	2017-01-27
PE20141406A1 (en)	2014-10-25
HUE030106T2 (en)	2017-04-28
EP3150601A1 (en)	2017-04-05
JP6059723B2 (en)	2017-01-11
GB201114103D0 (en)	2011-09-28
JO3187B1 (en)	2018-03-08
SI2744809T1 (en)	2017-01-31
US20140171462A1 (en)	2014-06-19
UY34264A (en)	2013-04-05

Publication	Publication Date	Title
CL2014000365A1 (en)	2014-07-11	Compound 4- (8-methoxy-1 - ((r) -1-methoxypropan-2-yl) -2- (tetrahydro-2h-pyran-4-yl) -1h-imidazo [4,5-c] quinolin- 7-yl) -3,5-dimethylisoxazole, brodominium inhibitor; pharmaceutical composition; pharmaceutical product; treatment procedure; and its use to treat an autoimmune and / or chronic inflammatory condition and cancer, among others.
WO2014062720A3 (en)	2014-06-19	Methods of treating cancer
CL2013000481A1 (en)	2013-11-22	Method and to improve the efficacy and / or reduce the side effects of a suboptimally administered pharmacotherapy comprising the administration of a substituted hexitol; pharmaceutical composition; pharmaceutical combination; Use to treat proliferative diseases.
CL2013000018A1 (en)	2013-05-10	Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
CL2015002658A1 (en)	2016-08-19	Derivatives of 2,3-disubstitute 1- acyl-4-amino-1,2,3,4-tetrahydroquiniline and its use as bromodomain inhibitors
CL2016001231A1 (en)	2017-01-20	Autotaxin Inhibitor Compounds
CL2014002557A1 (en)	2014-12-19	Bicyclic compounds of pyrazinone; preparation procedure; pharmaceutical composition; kit; and use in the treatment and / or prevention of cardiovascular diseases, cancer, among others.
CL2014001103A1 (en)	2014-10-03	Compounds derived from heteroaryl pyridone and substituted aza-pyridone, btk kinase inhibitors; pharmaceutical composition that includes them; process of preparation of the pharmaceutical composition; pharmaceutical kit; and use for the treatment of immune disorders, cancer, inflammation, neurological disorders, among others.
CL2008001633A1 (en)	2008-12-12	Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CL2012000772A1 (en)	2012-08-24	Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.
BR112013033940A2 (en)	2017-02-14	combination therapy comprising a cdk4 / 6 inhibitor and a pi3k inhibitor for use in cancer treatment
PE20120371A1 (en)	2012-05-17	3- [4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4YL) -1H-PYRAZOL-1-IL] OCTANE OR HEPTAN-NITRILE AS JAK INHIBITORS
CL2012000163A1 (en)	2012-07-13	Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
CL2013002177A1 (en)	2013-11-29	Compounds derived from 9h-purines and 7h-pyrrolo [2,3-d] -pyrimidines substituted, inhibitors of pi3k class i and / or mtor; its pharmaceutical composition; its pharmaceutical combination; and its use in the treatment or prevention of cancer or neurodegenerative disorders.
HK1213889A1 (en)	2016-07-15	Glutaminase inhibitors and method of use
IL258246B (en)	2021-10-31	Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
WO2013071056A3 (en)	2013-07-11	Combination drug therapy for the treatment of solid tumors
CL2013000735A1 (en)	2013-11-29	Use of a composition comprising compounds derived from substituted 1-h-imidazol-4-yl for the treatment of diseases and conditions of the skin, such as rosacea, chronic sun damage, psoriasis, among others; Pharmaceutical kit
WO2012158672A3 (en)	2014-05-08	Compounds for use in treatment of mucositis
CL2013000895A1 (en)	2013-09-27	Pharmaceutical combination comprising a compound derived from imidazo [4,5-c] -quinoline, pik3 / mtor inhibitor, an allosteric mtor inhibitor compound and optionally a pharmaceutically acceptable carrier; pharmaceutical composition; method to improve the effectiveness of the treatment; and its use in a proliferative disease.
CL2014000552A1 (en)	2014-09-12	Use of 4,4´- [fluoro- (1h-1,2,4-triazol-1-yl) methylene] bisbenzonitrile for the treatment of hypogonadism and oral pharmaceutical composition comprising the compound and pharmaceutical kit comprising the composition.
WO2012162513A3 (en)	2013-03-28	Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
WO2012024399A3 (en)	2013-06-27	Compositions comprising paulownin and/or paulownia extracts and uses thereof
CR20130488A (en)	2013-12-06	DERIVATIVES OF TIENO [2,3-D] PYRIMIDINE AND ITS USE TO TREAT ARRITMIA
HK1199832A1 (en)	2015-07-24	Combination therapy using ribavirin as eif4e inhibitor